We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 07, 2021

Monalizumab in Patients With Recurrent/Metastatic SCCHN

European Journal of Cancer


Additional Info

European Journal of Cancer
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
Eur. J. Cancer 2021 Nov 01;158(xx)17-26, R Galot, C Le Tourneau, E Saada-Bouzid, A Daste, C Even, P Debruyne, S Henry, S Zanetta, A Rutten, L Licitra, JL Canon, MC Kaminsky, P Specenier, S Rottey, J Guigay, A Kong, I Tinhofer, E Borcoman, L Dirix, T Raveloarivahy, C Fortpied, M Vanlancker, M Morfouace, AS Govaerts, JP Machiels

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading